LongeVC

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance understanding of biological functions and diseases. Unlike DNA sequencing, which offers limited insights, this next-generation platform provides deeper knowledge through single-molecule, massively parallel sequencing. By improving binding affinity and consistency, Glyphic's technology supports the creation of personalized and precision cancer vaccines tailored to individual patients. The company's innovative approach enables scientists and researchers to develop novel therapeutics and diagnostics, ultimately advancing the comprehension of human biology and disease mechanisms.

Catena Biosciences is a biotechnology company focused on advancing protein conjugation technology to develop novel therapeutics for autoimmune disorders, oncology, and vaccine development. The company specializes in the efficient and selective attachment of proteins using natural amino acids, specifically tyrosine and cysteine. This innovative approach allows researchers to create biologic structures more rapidly than traditional methods, enhancing the potential for medical research and treatment options in various disease areas. Catena Biosciences aims to contribute significantly to the field of biomedicine through its cutting-edge technology and applications.

Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing therapies that target senescent cells responsible for various age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of innovative therapeutic candidates. These candidates include novel small molecules designed to selectively address senescent cells, which contribute to the progression of several chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises experienced professionals from the fields of chemistry, technology, and life sciences, bringing a wealth of knowledge in drug development and commercialization.

Ani Biome is a longevity biotech startup that has the mission of optimizing and enhancing one's mind

Unnatural Products Inc. is a biotechnology company based in Santa Cruz, California, specializing in drug discovery through the innovative use of macrocyclic peptides. Founded in 2016, the company employs artificial intelligence and computational biology techniques to engineer these peptides, allowing them to target previously undruggable protein interactions. By leveraging machine learning for parallel chemical synthesis, Unnatural Products aims to optimize macrocyclic compounds efficiently, thereby accelerating the drug discovery process. This technology addresses a significant gap in therapeutic strategies, offering potential treatments for a wide range of diseases linked to difficult-to-target drug candidates.

Interface Biosciences is a therapeutics company focused on utilizing the microbiome to develop treatments for inflammatory diseases. The company creates therapeutic-microbial metabolite drugs that explore the interactions between the human microbiome and the immune system, aiming to address the underlying mechanisms of microbe-mediated immune cell activation and repression. Its modular drug development pipeline allows for targeting various biological pathways in both humans and microbes. The company’s research emphasizes the creation of multi-functional molecules to treat conditions such as eczema, inflammatory bowel disease (IBD), and oncology-related issues like premalignant lesions. This innovative approach enables healthcare professionals to manage chronic inflammatory diseases more effectively.

Haut.AI is a beauty technology company that specializes in artificial intelligence software for skin analysis and personalized product recommendations. Its flagship technology, Skin Atlas, combines advanced data privacy measures with comprehensive skin analysis capabilities. The software automates the collection of skin data, performing detailed assessments that calculate key metrics related to skin health and beauty. This information is then transmitted to customer applications, allowing skincare brands to offer tailored product testing and interactive recommendations on e-commerce platforms. By enabling customers, brands, and retailers to engage in a hyper-personalized skincare experience, Haut.AI enhances how skincare solutions are delivered in the digital marketplace.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Freedom Biosciences is a biotechnology platform focused on developing next-generation psychedelic therapeutics. The company aims to create innovative psychedelic pharmaceuticals by utilizing the established pharmacology of ketamine and other psychedelic compounds. This approach is intended to equip medical professionals with effective treatment options for patients suffering from resistant depression and various mental disorders.

PreComb is a technology company focused on enhancing cancer treatment outcomes through innovative solutions tailored for difficult-to-treat cancers. The company has developed a 3D drug testing technology that utilizes automated microtumor-based profiling for in vitro cancer diagnosis. This technology enables clinical institutions to conduct on-site evaluations, allowing for the functional assessment of various cancer drugs, combinations, and concentrations using patient-derived micro-tumors. By optimizing the selection of therapies, PreComb aims to improve success rates in cancer treatment and ultimately enhance the quality of life for patients.

Turn.bio is a biotechnology company focused on developing drugs aimed at reversing aging and age-related diseases. Leveraging its patented mRNA platform technology, known as ERA, the company addresses the effects of aging on the epigenome, thereby restoring optimal gene expression. Turn.bio’s innovative approach enables the body to heal itself by instructing specific cells to combat diseases or repair damaged tissues. The company targets a range of medical indications, including immune-related diseases such as cancer, dermatological conditions, ophthalmology, osteoarthritis, and issues related to the muscular system. Through its advanced delivery platform, eTurna, Turn.bio seeks to enhance the effectiveness of nucleic acid therapeutics in promoting health and longevity.

HelixNano is a biotechnology company focused on leveraging artificial intelligence and synthetic biology to develop innovative solutions for genetic diseases. Initially concentrating on cancer vaccines, the company is now pivoting to create COVID-19 vaccine candidates that prioritize precision and safety. HelixNano's platform enables the reliable expression of transgenes in humans, facilitating advancements in gene therapies and genome engineering. The company aims to not only address the current COVID-19 pandemic but also to develop vaccines that provide protection against all future coronaviruses. Through its work, HelixNano seeks to enable previously unattainable applications in both human and non-human biology, ultimately improving patient outcomes across a range of diseases.

First Longevity provides daily news and insights on the fast-growing longevity market. They offer antiaging, biotech, research, investment, supplements, and rejuvenation therapies. They offer news under diverse categories including AI, nanotechnology, drugs, agritech, and investment, along with monetizing its contents through display advertisements.

Deep Longevity, Inc. is a biotechnology company focused on advancing aging and longevity research through the development of aging clocks and biomarkers. Founded in 2016 and based in Hong Kong, the company offers a range of products including the Longevity Cloud, which hosts deep aging clocks, and Young.AI, a web and mobile application designed to assist individuals in monitoring their biological age. Deep Longevity also provides AgeMetric Reports for tracking longevity and employs an AI-based recommendation engine to suggest interventions for improving health outcomes. Its comprehensive approach incorporates various data types such as clinical blood tests, transcriptomic, proteomic, and microbiome information, enabling healthcare providers and aging centers to predict biological age with greater accuracy and support preventative medicine initiatives.